Drug intelligence / Profile preview

Bicun

Development stage: Unknown
Lead developer: Simcere Pharmaceutical Group
Modality: Small Molecules
Administration: Intravenous

Overview

Bicun is a branded injectable formulation of edaravone, developed by Simcere as the first edaravone solution for injection marketed in China and used as a central nervous system drug for stroke management and amyotrophic lateral sclerosis. It acts as a free radical scavenger and antioxidant, reducing oxidative stress to improve neurological function after acute ischemic stroke and to delay progression of amyotrophic lateral sclerosis. Bicun has been a core product in Simcere’s CNS portfolio and represents one of the company’s first-to-market generics in China.

Brand names: Bicun

Beyond the preview

Go deeper on Bicun.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bicun.

Explore the full profile